Clinical Trial Detail

NCT ID NCT03311334
Title A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

head and neck squamous cell carcinoma

renal cell carcinoma

melanoma

lung non-small cell carcinoma

transitional cell carcinoma

Therapies

Atezolizumab + DSP-7888

DSP-7888 + Nivolumab

Age Groups: senior adult

No variant requirements are available.